Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2024; 15(6): 717-729
Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.717
Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms
Mihnea-Alexandru Găman, Bahadar Singh Srichawla, Yong-Feng Chen, Poulami Roy, Arkadeep Dhali, Ahmed Nahian, Muhammad Romail Manan, Vincent Kipkorir, Richard Christian Suteja, Lakshmi Venkata Simhachalam Kutikuppala, Amelia Maria Găman, Camelia Cristina Diaconu
Mihnea-Alexandru Găman, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania
Mihnea-Alexandru Găman, Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest 022328, Romania
Mihnea-Alexandru Găman, Department of Cellular and Molecular Pathology, Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest 030304, Romania
Bahadar Singh Srichawla, Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States
Yong-Feng Chen, Department of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China
Poulami Roy, Department of Medicine, North Bengal Medical College and Hospital, West Bengal 734012, India
Arkadeep Dhali, Academic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, United Kingdom
Ahmed Nahian, Lecom at Seton Hill, Greensburg, PA 15601, United States
Muhammad Romail Manan, Faculty of Medicine, Services Hospital, Lahore 54000, Pakistan
Vincent Kipkorir, Department of Human Anatomy and Physiology, University of Nairobi, Nairobi 00100, Kenya
Richard Christian Suteja, Faculty of Medicine, Udayana University, Denpasar, Bali 80361, Indonesia
Lakshmi Venkata Simhachalam Kutikuppala, Department of General Surgery, Dr. NTR University of Health Sciences, Vijayawada 520008, Andhra Pradesh, India
Amelia Maria Găman, Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania
Amelia Maria Găman, Clinic of Hematology, Filantropia City Hospital, Craiova 200143, Romania
Camelia Cristina Diaconu, Department of Internal Medicine, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania
Camelia Cristina Diaconu, Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, Bucharest 105402, Romania
Author contributions: Găman MA contributed to the study conceptualization, data curation, funding acquisition, methodology, resources, validation, visualization, and software; Găman MA, Srichawla BS, Chen YF, Roy P, Dhali A, Nahian A, Manan MR, Kipkorir V, Suteja RC, and Simhachalam Kutikuppala LV contributed to the formal analysis, investigation, and writing of the original draft; Găman MA, Găman AM, and Diaconu CC contributed to the project administration and supervision; Găman MA, Srichawla BS, Găman AM, and Diaconu CC contributed to the writing, review, and editing.
Supported by the Grant Funded by Competitiveness Operational Programme A1.1.4. ID: P_37_798 MYELOAL-EDIAPROT (to Găman MA), No. 149/26.10.2016 (MySMIS2014+: 106774).
Conflict-of-interest statement: Dr. Găman reports grants from the Competitiveness Operational Programme A1.1.4. ID: P_37_798 MYELOAL-EDIAPROT, Grant Agreement No. 149/26.10.2016 (MySMIS2014+: 106774), during the conduct of the study. The other authors do not have any conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amelia Maria Găman, Doctor, MD, PhD, Doctor, Professor, Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Petru Rareş No. 2, Craiova 200349, Romania. gamanamelia@yahoo.com
Received: March 12, 2024
Revised: May 5, 2024
Accepted: May 28, 2024
Published online: June 24, 2024
Processing time: 103 Days and 14.6 Hours
Core Tip

Core Tip: The topic of dyslipidemia in myeloproliferative neoplasms (MPNs) has only been superficially studied to date. Although it is well known that cardiovascular risk factors impact the management of MPNs and increase the risk of thrombosis which is the main cause of death in MPNs, most investigations have overlooked dyslipidemia as a significant contributor to thrombotic risk and to the risk of death in MPNs. Herein, we provide, to the best of our knowledge, the first overview of lipid abnormalities in MPNs.